Impact of large language models on trial-to-patient matching efficiency.

N Nathan T. Rich (Utah Cancer Specialists, Salt Lake City, UT) S Sarah Salzman (Tempus AI, Inc, Chicago, IL) G Gabriel Altay (Tempus AI, Inc., Chicago, IL) K Kunal Nagpal (Tempus AI, Inc., Chicago, IL) V Vivek Shetye (Tempus AI, Inc., Chicago, IL) G Gena A Rangel (Tempus AI, Inc., Chicago, IL) P Poojan Thakkar (Tempus AI, Inc., Chicago, IL) A Annie Darmofal (Tempus AI, Inc., Chicago, IL) D Dan Sun B Bert O'Neil (Oncology, Community Health Network North Cancer Center, Indianapolis, IN) A Ahmad Zarzour (Toledo Clinic Cancer Center, Toledo, OH) J John Nemunaitis J James F. Maher (TriHealth Cancer Institute, Cincinnati, OH) P Philip E Lammers (Baptist Cancer Center, Memphis, TN) S Srilata Gundala (Hope & Healing Cancer Services, Hinsdale, IL) T Timothy J. Pluard (Saint Luke's Cancer Institute, Kansas City, MO) V Viran R. Holden (Oncology Hematology Associates, Springfield, MO) A Arpita Saha (Tempus AI, Inc., Chicago, IL) V Victoria L. Chiou (Tempus AI, Inc., Chicago, IL) C Chelsea Kendall Osterman (Tempus AI, Inc., Chicago, IL)

Abstract

e13600 Background: Timely and accurate clinical trial matching is critical to providing additional treatment options for patients, especially when standard-of-care treatments are limited. However, trial matching is time-consuming, leading to missed patient opportunities and delays in trial enrollment. The Tempus AI TIME Program utilizes a technology-enabled patient matching platform to improve screening efficiency and accelerate trial enrollment. TIME uses structured data followed by manual nurse review to assess patient eligibility. To enhance efficiency, we explored the incorporation of a retrieval augmented generation (RAG) question answering system based on large language models (LLMs) to evaluate additional unstructured data and prioritize patients for review. Methods: Using a phase 2 trial enrolling patients with advanced breast cancer, we identified potentially eligible patients based on high-level criteria including tumor type, stage, and biomarkers. We developed a set of LLM queries to assess additional eligibility criteria, such as the presence of comorbidities, second primary malignancy, or hospice care. For each query and patient, the RAG system retrieved 16 text snippets (approximately 1000 characters each) based on textual similarity to the prompt. These snippets and the query were input into GPT-4o to generate contextually relevant responses. A "match score" was then calculated for each patient (0-1, 1 = all queries satisfied). Nurse review was prioritized based on this score and each patient was assigned a trial status of "match" or "not a match". The match rate and time for patient review were evaluated. Results: Over two months, match scores were generated for 1,015 patients. In the first month, RAG system output and nurse feedback were used for prompt tuning, resulting in a final set of 13 queries. In the second month, these queries were used to optimize the screening of 508 patients. Patient review was prioritized by match score, and the match rate and number of patients matched over time were compared to a hypothetical random order scenario (Table 1). In both scenarios, the same 508 patients are reviewed, starting with 0 matched patients and ending with 66 matches. Patients with a match score of 1 had a 67% match rate compared to the average match rate of 13%. In addition, the optimized order resulted in more patient matches earlier in the process. Conclusions: The TIME program supports oncology practices by accelerating high-quality patient matching for clinical trials. Through a balanced process incorporating both LLMs and nurse verification, TIME demonstrated high efficiency gains for initial patient screening. Matching efficiency. Cumulative Patients Reviewed 21 160 351 473 508 Cumulative Review Time [hours] 3.5 27 59 79 85 Optimized Order  Match Score (s) s = 1 s ≥ 0.9 s ≥ 0.8 s ≥ 0.7 s > 0  Patients Matched 14 40 57 64 66  Match Rate 67% 25% 16% 14% 13% Random Order  Patients Matched 3 21 46 61 66  Match Rate 13% 13% 13% 13% 13%

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (20)

N

Nathan T. Rich

Utah Cancer Specialists, Salt Lake City, UT

S

Sarah Salzman

Tempus AI, Inc, Chicago, IL

G

Gabriel Altay

Tempus AI, Inc., Chicago, IL

K

Kunal Nagpal

Tempus AI, Inc., Chicago, IL

V

Vivek Shetye

Tempus AI, Inc., Chicago, IL

G

Gena A Rangel

Tempus AI, Inc., Chicago, IL

P

Poojan Thakkar

Tempus AI, Inc., Chicago, IL

A

Annie Darmofal

Tempus AI, Inc., Chicago, IL

D

Dan Sun

B

Bert O'Neil

Oncology, Community Health Network North Cancer Center, Indianapolis, IN

A

Ahmad Zarzour

Toledo Clinic Cancer Center, Toledo, OH

J

John Nemunaitis

J

James F. Maher

TriHealth Cancer Institute, Cincinnati, OH

P

Philip E Lammers

Baptist Cancer Center, Memphis, TN

S

Srilata Gundala

Hope & Healing Cancer Services, Hinsdale, IL

T

Timothy J. Pluard

Saint Luke's Cancer Institute, Kansas City, MO

V

Viran R. Holden

Oncology Hematology Associates, Springfield, MO

A

Arpita Saha

Tempus AI, Inc., Chicago, IL

V

Victoria L. Chiou

Tempus AI, Inc., Chicago, IL

C

Chelsea Kendall Osterman

Tempus AI, Inc., Chicago, IL